Skip to main content

Table 2 Kaplan-Meier analysis for the association between clinical features and occurrence of HCC or severe consequences of liver diseases in LAM-resistant chronic hepatitis B patients

From: Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B

Clinical and virological factors

No. of patients

HCC

Severe liver consequences

  

Cumulative incidence

P (Log Rank test)a

Cumulative incidence

P (Log Rank test)a

Sex

     

Male

101

5 (5.0%)

0.339

7 (6.9%)

0.775

Female

22

0 (0%)

 

1 (4.5%)

 

Age (years)

     

≦ 50

81

0 (0%)

0.001b

1 (1.2%)

0.001b

> 50

42

5 (11.9%)

 

7 (16.7%)

 

rtM204V

     

Absence

62

2 (3.2%)

0.589

2 (3.2%)

0.131

Presence

61

3 (4.9%)

 

6 (9.8%)

 

rtM204I

     

Absence

44

2 (4.5%)

0.857

3 (6.8%)

0.917

Presence

79

3 (3.8%)

 

5 (6.3%)

 

rtM204V+I

     

Absence

106

4(3.8%)

0.568

5 (4.7%)

0.033

Presence

17

1 (5.9%)

 

3 (17.6%)

 

rtL180M

     

Absence

89

3 (3.4%)

0.591

6 (6.7%)

0.830

Presence

34

2 (5.9%)

 

2 (5.9%)

 

rtA181T

     

Absence

113

2 (1.8%)

< 0.001b

4 (3.5%)

< 0.001b

Presence

10

3 (30.0%)

 

4 (40.0%)

 

HBeAg

     

Absence

58

5 (8.6%)

0.012

7 (12.1%)

0.016

Presence

65

0 (0%)

 

1 (1.5%)

 

HBV-DNA (×106 copies/mL)

     

≦ 15

69

2 (2.9%)

0.325

4 (5.8%)

0.570

> 15

54

3 (5.6%)

 

4 (7.4%)

 

AST

     

≦ 2 ×UNL

67

2 (3.0%)

0.337

2 (3.0%)

0.050

> 2 ×UNL

56

3 (5.4%)

 

6 (10.7%)

 

ALT

     

≦ 2 ×UNL

59

2 (3.4%)

0.722

3 (5.1%)

0.450

> 2 ×UNL

64

3 (4.7%)

 

5 (7.8%)

 

BCP mutation

     

Absence

64

0 (0%)

0.012

0 (0%)

0.002b

Presence

59

5 (8.5%)

 

7 (11.9%)

 

Precore stop codon mutation

     

Absence

67

1 (1.5%)

0.094

3 (4.5%)

0.285

Presence

56

4 (7.1%)

 

5 (8.9%)

 

Genotype C

     

Absence

84

3 (3.6%)

0.631

4 (4.8%)

0.234

Presence

39

2 (5.1%)

 

4 (10.3%)

 

Pre-S internal deletions

     

Absence

91

4 (4.4%)

0.749

6 (6.6%)

0.941

Presence

32

1 (3.1%)

 

2 (6.3%)

 

Duration of LAM treatment on entry (months)

     

≦ 12

80

2 (2.5%)

0.798

4 (5.0%)

0.361

> 12

43

3 (7.0%)

 

4 (9.3%)

 

Subsequent ADV treatment

     

No

41

1 (2.4%)

0.688

2 (4.9%)

0.774

Yes

82

4 (4.9%)

 

6 (7.3%)

 

Subsequent ETV treatment

     

No

79

4 (5.1%)

0.422

0 (0%)

0.153

Yes

44

1 (2.3%)

 

8 (18.2%)

 

Subsequent ETV and/or ADV treatment

     

No

21

1 (4.8%)

0.284

1 (4.8%)

0.181

Yes

102

4 (3.9%)

 

7 (6.9%)

 

Total duration of antiviral therapy (months)

     

≦ 40

73

1 (1.4%)

0.157

3 (4.1%)

0.343

> 40

50

4 (8.0%)

 

5 (10%)

 

Cirrhosis

     

No

83

0 (0%)

< 0.001b

0 (0%)

< 0.001b

Yes

40

5 (12.5%)

 

8 (20.0%)

 
  1. aKaplan-Meier analysis; bAccording to the method of Bonferroni correction for multiple comparisons, P < 0.0024 was considered statistically significant.